EZH2 and mesothelioma: As illustrated in Figure 8A, overexpressed EZH2 was associated with unfavorable OS of patients with adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), LGG, LIHC, mesothelioma (MESO), pheochromocytoma and paraganglioma (PCPG), and PRAD.